Global Chorea Treatment Market – Industry Trends and Forecast to 2030

Global Chorea Treatment Market, By Type (Sydenham’s Chorea and Chorea-Acanthocytosis), Treatment (Medication, Surgeries and Others), Drugs Class (Antipsychotic Drugs and Benzodiazepines Drugs), Symptoms (Involuntary Muscle Movements, Milkmaid’s Grip, Speech Problems and Seizures), End-Users (Clinics, Hospitals, Ambulatory Surgical Centres and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) – Industry Trends and Forecast to 2030.

Chorea Treatment Market Analysis and Size

Primary chorea, also known as Huntington's disease (HD), is an inherited neurodegenerative disorder. The incidence of HD is estimated to be around 2 to 7 per 100,000 individuals worldwide. It affects both males and females, typically presenting in adulthood, although there are cases of juvenile-onset HD as well. Secondary chorea can be caused by various factors, including certain medications, metabolic disorders, autoimmune conditions, infections, and brain injuries. The incidence of secondary chorea depends on the specific underlying cause and may vary widely.

Data Bridge Market Research analyses that the global chorea treatment market which was USD 651.57 million in 2022, is expected to reach USD 962.66 million by 2030, and is expected to undergo a CAGR of 5.0% during the forecast period 2023-2030. This indicates the market value. “Medication” dominates the type segment of the global chorea treatment market owing to the growing demand for better methods for treatment in chorea patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Chorea Treatment Market Scope and Segmentation

Market Definition

Chorea is referring as a motion disorder which induces unpredictable, irregular, and involuntary muscle movements. Growing awareness regarding chorea symptoms among populace anticipated to enhance the chorea treatment market’s growth rate. The disorder can make individual glance like restless or dancing or fidgety.

Global Chorea Treatment Market Dynamics

Drivers

• Increasing Prevalence of Gastrointestinal Disorders

The rising incidence of gastrointestinal disorders such as colorectal cancer, esophageal cancer, gastric outlet obstruction, and inflammatory bowel disease (IBD) is driving the demand for GI stents. These conditions often require stent placement to relieve symptoms and improve the patient's quality of life.

• Growing Aging Population

The global population is aging, leading to an increased prevalence of age-related conditions like gastrointestinal strictures and cancers. As the elderly population grows, there is a higher demand for GI stents to manage these conditions.

Opportunities

• Expansion of Endoscopic Procedures

Endoscopic procedures, including endoscopic stent placement, are becoming increasingly common for the treatment of gastrointestinal disorders. The expansion of endoscopic techniques, such as endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), provides opportunities for GI stent manufacturers to develop specialized stents for these procedures.

• Focus on Patient-Centric Approaches

Patient comfort, quality of life, and long-term outcomes are crucial considerations in GI stent placement. Companies that prioritize patient-centric approaches, such as designing stents with improved biocompatibility, reduced migration rates, and better ease of removal, can gain a competitive advantage and capture market share.

Restraints/Challenges

• Complications and Adverse Events

Despite advancements in GI stent technology, complications and adverse events can occur. These can include stent migration, perforation, bleeding, infection, and tissue overgrowth. Such complications can lead to additional treatments, hospitalizations, and increased healthcare costs. Addressing and minimizing these complications is essential for the market's growth.

• Availability of Alternative Treatment Options

In certain cases, alternative treatment options may be available for gastrointestinal conditions, such as surgical interventions or other minimally invasive procedures. The availability of these alternatives can limit the demand for GI stents and pose a challenge for market growth. Manufacturers need to demonstrate the clinical and economic benefits of stent placement compared to alternative treatments.

This global chorea treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global chorea treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In December 2020, Boston Scientific announced the launch of its WallFlex Biliary RX Fully Covered Stent with Controlled Release Technology in the United States. The stent is designed to provide controlled release of a drug to help prevent tissue overgrowth
• In November 2020, Cook Medical received FDA clearance for its Evolution Controlled-Release Esophageal Stent. The stent features a dual-layer design that aims to reduce the risk of tissue overgrowth and migration.

Chorea Treatment Market Scope

The global chorea treatment market is segmented on the basis of type, treatment, drugs class, symptoms, end users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Sydenham’s Chorea
• Chorea-Acanthocytosis

Treatment

• Medication
• Surgeries
• Others

Drugs Class

• Antipsychotic Drugs
• Benzodiazepines Drugs

Symptoms

• Involuntary Muscle Movements
• Milkmaid’s Grip
• Speech Problems
• Seizures

End Users

• Clinics
• Hospitals
• Ambulatory Surgical Centres
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Chorea Treatment Market Regional Analysis/Insights

The global chorea treatment market is analysed and market size insights and trends are provided by country, type, treatment, drugs class, symptoms, end users and distribution channel as referenced above.

The countries covered in the global chorea treatment market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.

North America dominates the global chorea treatment market because of the strong base of healthcare facilities, presence of high healthcare expenditure and growing research and development activities by major market players for advanced chorea treatment.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, constant rise in geriatric population and growing number of partnership and acquisition agreement by major market players in emerging countries.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global chorea treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global chorea treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global chorea treatment market.

Competitive Landscape and Global Chorea Treatment Market Share Analysis

The global chorea treatment market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global chorea treatment market.

Some of the major players operating in the global chorea treatment market are:

• Medtronic plc. (Ireland)
• Boston Scientific Corporation (U.S.)
• ALEVA NEUROTHERAPEUTICS SA (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc. (U.K.)
• Bausch Health Companies Inc. (Canada)
• LivaNova, PLC (U.K.)
• H. Lundbeck A/S (Denmark)
• Ipsen (France)
• Alnylam Pharmaceuticals Inc. (U.S.)
• Prana Biotechnology Ltd. (Australia)
• RespireRx Pharmaceuticals Inc. (U.S.)
• Vertex Pharmaceuticals, Inc. (U.S.)
• SOM Innovation Biotech, S.A. (Spain)